Risk Models and Prognostic Factors

Video

Robert Alter, MD comments on the use of prognostic models for determining risk status and informing treatment options in patients with RCC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Episode 6: Updates on Genitourinary Cancer Therapies from ASCO 2025
      Various methods of communication ensure that members from radiation oncology, pathology, and other departments are on the same page regarding treatment.
      Making a ‘World of Difference’ Via Multidisciplinary Care in GI, GU Cancers
      Comprehensive prehabilitation may help prepare patients for bladder-preserving surgery, helping to optimize quality of life outcomes.
      Reviewing QOL Strategies/Considerations Following Bladder Cancer Surgery
      Ongoing research suggests environmental exposures and the role of microbiomes may influence bladder cancer development and response to treatment.
      Outlining Risk Factor Identification and Mitigation in Bladder Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      Episode 4: Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer
      How a Radiation Oncologist Answers Patient Questions with Research
      How a Radiation Oncologist Answers Patient Questions with Research
      There Is Excitement and Advances in SBRT Treatment For RCC
      There Is Excitement and Advances in SBRT Treatment For RCC
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Radiation Oncology in Prostate Cancer Is Advancing Thanks to Technology and Time
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      Strong Collaboration is Essential for Radiation Oncologists and Other Experts
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      The Effect of Dato-DXd Targeting TROP2 in Urothelial Cancer
      Related Content
      The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

      CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer

      Roman Fabbricatore
      June 3rd 2025
      Article

      The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.

      A Sneak Peek at 2025 ASCO From the GU Perspective

      A Sneak Peek at 2025 ASCO From the GU Perspective

      Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
      May 15th 2025
      Podcast

      Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, highlight exciting trials in the genitourinary cancer space expected to be presented at 2025 ASCO.

      Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

      ODAC Votes 8-to-0 Against First-Line Talazoparib/Enzalutamide in mCRPC

      Roman Fabbricatore
      May 21st 2025
      Article

      Eight votes were cast against the favorability of talazoparib and enzalutamide in the first-line setting for patients with metastatic castration-resistant prostate cancer.

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Beyond Surgery: The Evolving Landscape of Adjuvant Therapy in Kidney Cancer

      Manojkumar Bupathi, MD, MS;Manojkumar Bupathi, MD, MS
      May 1st 2025
      Podcast

      Oncology Decoded hosts discuss adjuvant therapy in kidney cancer, including research, treatment strategies, and management of recurrence.

      Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

      Durvalumab Combo Demonstrates DFS Improvement in High-Risk NMIBC

      Roman Fabbricatore
      May 9th 2025
      Article

      Data from the POTOMAC trial evaluating durvalumab in NMIBC will be presented at a future medical meeting and shared with global regulatory authorities.

      No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.

      EVP Before Consolidative Surgery Optimizes Responses in Urothelial Cancer

      Sabrina Serani
      May 2nd 2025
      Article

      No 90-day mortality was observed among patients who were treated with EVP followed by surgery for advanced urothelial cancer.